m.ekstrom

TL2 · Utrecht

Contributes reviews on supplier material. Based in Utrecht.

Joined 14 February 2025 · last posted 21h

68 posts, newest first. Showing up to 150.

Publication patterns in the BPC-157 literature, examined Replied, post #46 · Compounds › Repair & healing peptides · 27 Jul 2026 · 10 likes Post #42 describes the usual case. This is about the unusual one. TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #96 · Practice › Dosing & titration · 25 Jul 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #9 · Clinical › Bloodwork · 17 Jul 2026 · 12 likes The thing about egfr fluctuation that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #36 · Compounds › Repair & healing peptides · 17 Jul 2026 · 4 likes For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or…
Common supplements people ask about, assessed one at a time Replied, post #55 · Practice › Interactions · 16 Jul 2026 · 12 likes Common supplements was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #83 · Analytics › Home & field testing · 14 Jul 2026 · 21 likes A home refractometer is not measuring what people hope it is measuring in these preparations, and the readings are dominated by everything other than the peptide.
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #62 · Analytics › Home & field testing · 7 Jul 2026 · 3 likes Adding the boring version of consumer-accessible tests, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary…
A structured critique template this community uses — a second dataset Replied, post #29 · Evidence › Study critique · 5 Jul 2026 · 0 likes Narrowing post #28, because the general version has more than one answer. Per-protocol and intention-to-treat analyses answer different questions and neither is the…
Alcohol: what is documented and what is folklore Replied, post #83 · Practice › Interactions · 29 Jun 2026 · 25 likes Post #80 answers the question as asked. The question underneath it is different. Where a published interaction study exists it usually reports an area-under-curve…
Mass error in ppm: the arithmetic and the caveat — a second dataset Replied, post #12 · Analytics › Mass spectrometry · 23 Jun 2026 · 20 likes Purity and identity are different questions: LC-MS establishes that the species at a retention time has the expected mass. It does not establish how much of the sample…
Request: tag synonyms surfaced in search Replied, post #5 · Meta › Feature requests · 23 Jun 2026 · 2 likes Bookmarking this. I will come back when I have something worth adding.
[2026 update] Are there stupid questions here? A staff answer, at length Replied, post #41 · Start Here › Welcome · 19 Jun 2026 · 19 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Pooling trials with different estimands Replied, post #6 · Evidence › Meta-analyses · 4 Jun 2026 · 0 likes Worth separating two things that post #4 runs together. My experience of pooling trials with different estimands contradicts the reply above. I am posting it as a data…
The best-written scientific paper you have read Replied, post #70 · Lounge › Off topic · 28 May 2026 · 22 likes Two sentences on best-written scientific paper and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is…
Follow-up: A parcel that arrived warm: a decision process, not a verdict Replied, post #29 · Practice › Storage & stability · 16 May 2026 · 28 likes The arithmetic in post #27 is right; the assumption feeding it is the part to check. Visible particulate is a strong signal in the other direction: it is a reason to…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #29 · Practice › Reconstitution · 29 Apr 2026 · 1 like The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common arithmetic error in this subcategory. The habit that catches it:…
Why the timeline is on the right and not the left — what changed since Replied, post #26 · Meta › Site feedback · 26 Apr 2026 · 0 likes Confirming post #24 from a second method, which matters more than confirming it from a second person. An honest declaration on timeline: I have a prior here and it is…
Prescription portability between countries Replied, post #7 · Access › International · 13 Apr 2026 · 8 likes Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not…
Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #26 · Practice › Administration · 12 Apr 2026 · 21 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life.
Choosing which test to pay for, given a fixed budget Replied, post #49 · Sourcing › Independent verification · 1 Apr 2026 · 0 likes Picking up post #46: that is the part I would want checked first. It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #91 · Access › Pricing · 16 Feb 2026 · 0 likes I changed my mind about Price changes after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #51 · Outcomes › Progress reports · 14 Feb 2026 · 20 likes Answering the question post #47 raises rather than the one it answers. What I can speak to on Seven-day rolling is narrow, so I will keep it narrow rather than…
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #86 · Wellbeing › Mental health · 3 Feb 2026 · 14 likes Post #83 answers the question as asked. The question underneath it is different. If you are in crisis, contact a local emergency or crisis service rather than posting.…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #38 · Sourcing › Red flags · 5 Jan 2026 · 0 likes Nothing here should be read as an accusation against a named company, and the guidelines exist so that reports remain reports. Happy to be the one who is wrong here if…
Oral semaglutide bioavailability and its variability between people Replied, post #22 · Compounds › Oral incretins · 20 Dec 2025 · 26 likes Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving…
Robustness: the parameters worth deliberately varying Replied, post #40 · Analytics › Method validation · 4 Dec 2025 · 17 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. On balance I think that is…
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #26 · Data & Tools › Calculators · 3 Dec 2025 · 0 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Feature request, because it is the sort of subject where it…
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #10 · Practice › Side effects · 22 Nov 2025 · 11 likes Where I part company with post #8, and it is a narrow parting. The published rates come from populations that were titrated on a defined schedule with clinical…
Second pass at: The mass-error checker and its intended scope Replied, post #69 · Data & Tools › Calculators · 21 Nov 2025 · 0 likes Mass-error checker: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Thyroid function tests during substantial weight change Replied, post #122 · Clinical › Bloodwork · 5 Nov 2025 · 11 likes Source for the thyroid function tests during substantial figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version…
Can a home kit substitute for a laboratory report? A careful no Replied, post #43 · Analytics › Home & field testing · 31 Oct 2025 · 9 likes The most useful home practice is not a test at all: photograph the vial, the cake, the label and the document on arrival. It costs nothing and it is the evidence you…
Reading a supplier's product description as a marketing document Replied, post #89 · Compounds › Other compounds · 26 Oct 2025 · 0 likes Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end…
How to read a phase 2 result without treating it as a phase 3 result — what changed since Replied, post #11 · Compounds › Retatrutide · 22 Oct 2025 · 0 likes Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm…
Sleep tracking data and its considerable limitations Started this topic · Wellbeing › Sleep · 13 Oct 2025 · 22 likes Sleep tracking data and its considerable limitations — setting out what I have, and where I think it stops being reliable. A measurement question rather than a…
Publishing an inconvenient result: a case study — the long version Replied, post #5 · Sourcing › Independent verification · 8 Oct 2025 · 3 likes The opening post and I disagree about the size of the effect, not about the direction. Verification records are dated because they expire in usefulness. A result from…
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #143 · Data & Tools › Calculators · 7 Oct 2025 · 2 likes The most common input error is entering the vial mass in the concentration field. It produces a plausible number, which is why it survives. I have separated what I…
What a purity-only report leaves out Replied, post #21 · Sourcing › Independent verification · 21 Sep 2025 · 3 likes Post #18 is right about the mechanism and I think understates the practical bit. I read the earlier replies on purity-only twice before writing this, because I had…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #56 · Data & Tools › Datasets · 8 Sep 2025 · 0 likes Post #54 describes the usual case. This is about the unusual one. The documentation on Aggregated purity results across four is better than this thread and I say that…
Confounding by indication, explained with a concrete example Replied, post #8 · Evidence › Study critique · 31 Aug 2025 · 11 likes Surrogate endpoints are not automatically bad and their validity is compound-specific and population-specific. The question is whether this surrogate has been validated…
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #30 · Compounds › Secretagogues & GH axis · 2 Aug 2025 · 26 likes That is a fair summary of where the discussion has got to.
Are there stupid questions here? A staff answer, at length Replied, post #19 · Start Here › Welcome · 28 Jul 2025 · 14 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Coming back to: What published stability data actually covers, and what it does not Replied, post #87 · Practice › Storage & stability · 14 Jul 2025 · 0 likes Everything in post #85 holds. The case it does not cover is the one I have. The practical version of published stability data actually covers is three sentences long.…
Second pass at: Reading a combination trial: attributing effect to components Replied, post #28 · Compounds › Cagrilintide & amylin analogues · 15 Jun 2025 · 0 likes Narrowing post #27, because the general version has more than one answer. The interest in combining it with semaglutide is that two different satiety mechanisms might…
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #28 · Evidence › Journal club · 6 Jun 2025 · 14 likes An hour is enough for one paper read properly and not enough for two read partly. The temptation is always to add the second. I am not the right person to answer the…
Risk-of-bias tools and the judgement they conceal Replied, post #4 · Evidence › Meta-analyses · 3 Jun 2025 · 0 likes Source for the risk-of-bias tools figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger…
Pregnancy as an absolute contraindication Replied, post #97 · Safety › Contraindications · 20 May 2025 · 1 like Pregnancy was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Follow-up: Documentation that appears only after payment Replied, post #74 · Sourcing › Red flags · 13 May 2025 · 11 likes The most useful contribution to this subcategory is a resolved case written up with the resolution, because the unresolved ones are all anyone remembers. That is the…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #78 · Compounds › Tirzepatide · 6 May 2025 · 12 likes Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different…
Reporting a disappointing outcome, and why it belongs here Replied, post #9 · Outcomes › Progress reports · 5 Apr 2025 · 23 likes Saving this. It is the version I will quote when the question comes round again.
Follow-up: What other technical communities get right that we do not Replied, post #52 · Lounge › Off topic · 29 Mar 2025 · 0 likes Unserious but true: I can now identify a certificate template at a glance and I have no professional use for that skill whatsoever. The variance between people here is…
Obstructive sleep apnoea and a hard endpoint in this class Replied, post #40 · Clinical › Comorbidities · 23 Mar 2025 · 15 likes Picking up post #38: that is the part I would want checked first. Gastrointestinal conditions interact with a mechanism that slows gastric emptying in ways that are…
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #108 · Access › International · 19 Mar 2025 · 0 likes This follows post #105 rather than contradicting it. Answering the Cross-border purchase within question as asked, then the question I think is meant. As asked: yes,…
Maintainer handover: how it works Replied, post #36 · Meta › Wiki maintenance · 15 Mar 2025 · 10 likes Maintainer handover is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says…
Validating a method you did not develop — does this still hold? Replied, post #43 · Analytics › Method validation · 25 Feb 2025 · 4 likes Where I part company with post #39, and it is a narrow parting. The most useful single question about a method: what would it fail to detect? Every method has an answer…
Talking to a therapist about this specifically — does this still hold? Replied, post #16 · Wellbeing › Mental health · 12 Feb 2025 · 3 likes The social side of this — how other people respond to visible change — comes up constantly and has nothing to do with pharmacology.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #22 · Practice › Reconstitution · 29 Jan 2025 · 5 likes An update on my earlier 5 mg vial post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
The topic list is dense — is that deliberate? Replied, post #83 · Meta › Site feedback · 15 Jan 2025 · 0 likes Confirming post #80 from a second method, which matters more than confirming it from a second person. Last piece of feedback: the site is much better on a narrow screen…
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #50 · Compounds › Semaglutide · 28 Dec 2024 · 20 likes One more thing on Semaglutide formulation that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #8 · Compounds › Semaglutide · 18 Dec 2024 · 4 likes Post #7 describes the usual case. This is about the unusual one. On the injection-day question: the labelling for licensed semaglutide allows the day to be changed…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #92 · Compounds › Tirzepatide · 16 Dec 2024 · 30 likes Injection-site reactions were reported at a low but non-zero rate across the trials. The practical point is that a reaction at one site does not predict a reaction at…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #31 · Compounds › Cagrilintide & amylin analogues · 5 Dec 2024 · 15 likes Careful with the language on amylin analogue mechanism. "Not detected" and "not present" are different findings and the first is a statement about the method.
Time to steady state after a dose increase Replied, post #16 · Pharmacology › Pharmacokinetics · 2 Nov 2024 · 3 likes Building on post #15 rather than restating it. The accumulation ratio for weekly dosing with a week-long half-life is around two, which is why the concentration after…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #10 · Access › Insurance & coverage · 31 Oct 2024 · 26 likes For anyone finding this later: the short answer on Step therapy requirements is that it depends on one thing, and the rest of the thread is people identifying which…
When a red flag was a misunderstanding, and the retraction Replied, post #36 · Sourcing › Red flags · 18 Oct 2024 · 1 like Picking up post #35: that is the part I would want checked first. Evasion when asked: if a supplier does not clarify when asked specifically for method details,…
Circumference measurements as a poor man's composition estimate Replied, post #38 · Outcomes › Body composition · 3 Aug 2024 · 31 likes Adding a data point of agreement rather than a data point.
Guidelines revision: what changed and why Replied, post #87 · Meta › Announcements · 27 Jul 2024 · 6 likes Everything in post #83 holds. The case it does not cover is the one I have. Archives: older announcements are archived by date. Checking archives is useful if you want…
How to ask for a dose change without antagonising anyone Replied, post #3 · Clinical › Prescriber conversations · 5 Jul 2024 · 31 likes That matches what I have seen, for whatever a single anecdote is worth.
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #10 · Practice › Dosing & titration · 7 Jun 2024 · 8 likes I changed my mind about four-week escalation interval after someone here asked me for the source and I could not produce one. That is worth saying out loud because it…